Supernus Pharmaceuticals's total assets for Q1 2025 were $1.35B, a decrease of -1.52% from the previous quarter. SUPN total liabilities were $316.58M for the fiscal quarter, a -4.74% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.